The Future of ePRO Platforms
It is tempting to imagine the use of the patient’s own mobile computing platform for collection of patient reported outcomes.
It is tempting to imagine the use of the patient’s own mobile computing platform for collection of patient reported outcomes. This would solve some of the problems faced when using the e-PRO devices employed today:
- Provisioning costs (purchasing or leasing the devices to be used in the trial)
- Supply issues (delivering the devices to the sites for distribution to subjects, and collection after the subject completes the trial)
- Training (handling and use of the device by subjects and site staff)
- Maintenance and Help Desk (device-related help desk questions, replacement of faulty devices)
Click here for an Applied Clinical Trials article by Alan Yeomans that evaluates the practicality of such an approach, and the issues that need to be addressed if it is to succeed.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
